Argenx pays up to $1.15b for a peptide firm

Coverage, in order

1. 11h ago
   
   Longevity.Technology UK indie

   Argenx pays up to $1.15b for a peptide firm

   The immunology company is buying Unnatural Products to chase oral and long-acting medicines for serious immune-mediated diseases. For people with long-running immune-mediated conditions, treatment can stretch across years, so how a medicine is delivered becomes part of daily life. That is the…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.